Alterity Therapeutics (ASXATH) has unveiled a new commercial assessment of its lead candidate ATH434, positioning the therapy as a potential first-in-class treatment for Multiple System Atrophy, a rare and debilitating Parkinsonian disorder with no approved therapies. …
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News